Medtech Insight is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


MolDx Labs Question Missing Medicare Payment Amounts For Some Test Codes

This article was originally published in The Gray Sheet

Executive Summary

Clinical laboratories plan to talk to CMS about its decision to list only 65 out of 114 new molecular pathology codes when it released revised gap-fill pricing Sept. 30, as well as concerns about perceived changes to the gap-fill regulation.


Related Content

New CMS Lab Test Panel Meets To Make Payment Policy Recommendations
Uncertainty Over BRCA Testing Reimbursement Remains
CMS Director To Diagnostics Industry: Prove Your Cancer Tests Work
Reimbursement Briefs: National Coverage Updates; MolDx Meeting Request; Sleep Study Questions
Lab Tests Face Revaluation, Cuts Under New CMS Proposals
Molecular Dx Labs’ Concerns Shift To Coverage Issues With Release Of Interim Medicare Payment Amounts
Personalized Medicine And Palmetto’s MolDx: Raising The Bar On Evidence
CMS In Brief
Industry Groups Push CMS To Pay For Algorithms In Multi-Analyte Tests



Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts